




Fig. S1. Changes in lichenification scores during study FLT001, a 4-week multicentre double-blind study to compare safety and efficacy between once daily (OD) and twice daily (BD) administration of fluticasone propionate cream in the treatment of atopic dermatitis. Lichenification criteria: 0: absent, 0.5: very mild, 1.0: mild, 1.5: mild to moderate, 2.0: moderate, 2.5: severe, 3.0: very severe.




Fig. S2. Changes in lichenification scores during study FLT002, a 4-week multicentre double-blind study to compare safety and efficacy between once daily (OD) and twice daily (BD) administration of fluticasone propionate ointment in the treatment of atopic dermatitis. Lichenification criteria: see Fig. S1.




Fig. S3. Changes in lichenification scores during study FLT401, a 4-week multicentre double-blind study to compare safety and efficacy between once daily (OD) and twice daily (BD) administration of fluticasone propionate ointment and placebo ointment in the treatment of atopic dermatitis. Lichenification criteria: see Fig S1.

Table SI. Number of patients in the analysed studies with their lichenification scores at the start of acute treatment. For a characterisation of the studies see Materials & Methods (n = 749)

Study	Lichenification score						
	0	0.5	1.0	1.5	2.0	2.5	3.0
FLT001 OD	2	6	14	15	65	21	14
FLT001 BD	1	3	19	11	70	17	12
FLT002 OD	0	0	6	10	53	32	22
FLT002 BD	0	0	2	13	57	25	25
FLT401 OD	3	9	19	6	26	7	9
FLT401 BD	4	5	21	5	27	6	11
FLT401plac	6	7	15	6	21	12	9
Total	16	30	96	66	319	120	102

Lichenification criteria: 0: absent; 0.5: very mild; 1.0: mild; 1.5: mild to moderate; 2.0: moderate; 2.5: severe; 3.0: very severe.

OD: once daily; BD: twice daily; plac: placebo.

Table SII. Distribution characteristics of lichenification by study, by treatment and by week. For a description of the studies see Material and Methods

Week	Study	Treatment	n	Mean $\pm$ SD	Median	Min–Max
0	FLT001	OD	137	1.93 $\pm$ 0.65	2	0–3
		BD	133	1.92 $\pm$ 0.60	2	0–3
		Total	270	1.92 $\pm$ 0.63	2	0–3
	FLT002	OD	123	2.22 $\pm$ 0.52	2	1–3
		BD	122	2.24 $\pm$ 0.49	2	1–3
		Total	245	2.23 $\pm$ 0.50	2	1–3
	FLT401	Placebo	76	1.66 $\pm$ 0.89	2	0–3
		OD	79	1.63 $\pm$ 0.82	2	0–3
		BD	79	1.68 $\pm$ 0.83	2	0–3
		Total	234	1.66 $\pm$ 0.85	2	0–3
	Total	Placebo	76	1.66 $\pm$ 0.89	2	0–3
		OD	339	1.96 $\pm$ 0.69	2	0–3
		BD	334	1.98 $\pm$ 0.66	2	0–3
1	FLT001	OD	132	1.38 $\pm$ 0.71	1.5	0–3
		BD	125	1.36 $\pm$ 0.71	1.5	0–3
	FLT002	OD	118	1.64 $\pm$ 0.68	1.5	0–3
		BD	118	1.57 $\pm$ 0.71	1.5	0–3
	FLT401	Placebo	74	1.39 $\pm$ 0.79	1.5	0–3
		OD	77	1.01 $\pm$ 0.68	1	0–3
		BD	77	0.91 $\pm$ 0.74	1	0–3
	Total	Placebo	74	1.39 $\pm$ 0.79	1.5	0–3
		OD	327	1.38 $\pm$ 0.73	1.5	0–3
		BD	320	1.33 $\pm$ 0.76	1.5	0–3
2	FLT001	OD	122	0.96 $\pm$ 0.74	1	0–2.5
		BD	117	0.92 $\pm$ 0.70	1	0–3
	FLT002	OD	104	1.26 $\pm$ 0.74	1	0–3
		BD	107	1.22 $\pm$ 0.69	1	0–3
	FLT401	Placebo	63	1.13 $\pm$ 0.92	1	0–3
		OD	73	0.70 $\pm$ 0.65	0.5	0–2.5
		BD	74	0.68 $\pm$ 0.64	0.5	0–2.5
	Total	Placebo	63	1.13 $\pm$ 0.92	1	0–3
		OD	299	1.00 $\pm$ 0.75	1	0–3
		BD	298	0.97 $\pm$ 0.71	1	0–3
3	FLT001	OD	109	0.78 $\pm$ 0.69	1	0–2.5
		BD	111	0.76 $\pm$ 0.67	0.5	0–3
	FLT002	OD	96	1.07 $\pm$ 0.72	1	0–3
		BD	92	1.13 $\pm$ 0.73	1	0–3
	FLT401	Placebo	56	1.01 $\pm$ 0.88	1	0–3
		OD	69	0.54 $\pm$ 0.58	0.5	0–2.5
		BD	69	0.56 $\pm$ 0.63	0.5	0–2.5
	Total	Placebo	56	1.01 $\pm$ 0.88	1	0–3
		OD	274	0.82 $\pm$ 0.70	1	0–3
		BD	272	0.83 $\pm$ 0.71	1	0–3
4	FLT001	OD	99	0.65 $\pm$ 0.64	0.5	0–2
		BD	98	0.59 $\pm$ 0.60	0.5	0–2
	FLT002	OD	83	1.02 $\pm$ 0.64	1	0–2.5
		BD	80	1.07 $\pm$ 0.71	1	0–2.5
	FLT401	Placebo	53	0.95 $\pm$ 0.86	1	0–3
		OD	62	0.38 $\pm$ 0.54	0	0–2.5
		BD	57	0.40 $\pm$ 0.54	0	0–2.5
	Total	Placebo	53	0.95 $\pm$ 0.86	1	0–3
		OD	244	0.71 $\pm$ 0.67	0.5	0–2.5
		BD	235	0.71 $\pm$ 0.68	0.5	0–2.5

OD: once daily; BD: twice daily; mean: mean lichenification score; SD: standard deviation; Min: minimum lichenification score; Max: maximum lichenification score.

Lichenification criteria: 0: absent, 0.5: very mild, 1.0: mild, 1.5: mild to moderate, 2.0: moderate, 2.5: severe, 3.0: very severe.

Table SIII. Elements of the random disturbances around the mean regression lines, represented by the between-subjects variability of intercepts and slopes and by the within-subject variability of the serially correlated residuals

Variability parameter	FLT001	FLT002	FLT401	3 studies
Between-subjects model variability				
Standard deviation (intercept)	0.385	0.247	0.737	0.496
Standard deviation (slope)	0.248	0.235	0.330	0.270
Correlation (intercept, slope)	-0.23	0.92	-0.65	-0.30
Within-subjects residual variability				
Autocorrelation (1 st order)	0.51	0.37	0.48	0.45
Standard deviation (residual)	0.498	0.441	0.419	0.451